Recent Progress of Imaging Agents for Parkinson’s Disease

Author(s): Xiaoai Wu, Huawei Cai, Ran Ge, Lin Li, Zhiyun Jia

Journal Name: Current Neuropharmacology

Volume 12 , Issue 6 , 2014

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Parkinson’s disease (PD) is a common progressive, neurodegenerative brain disease that is promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements in radionuclide imaging in Parkinson’s disease.

Keywords: Neurodegenerative, Parkinson’s disease, radiopharmaceuticals.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [551 - 563]
Pages: 13
DOI: 10.2174/1570159X13666141204221238
Price: $65

Article Metrics

PDF: 17